This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Amarex Clinical Research guides its client to phase II of FDA trials
Tislelizumab is now approved in nine indications in China
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Healthcare is timely and personal – and its delivery should be too
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
Subscribe To Our Newsletter & Stay Updated
